All these results show that CpG ODN TLR9 stimulation is the potent enhancer of tumor response and as such has a potential to improve clinical radiotherapy bearing in mind that standard CpG oligonucleotides have been shown to be highly active in murine models while showing limited activity in humans. Here, TLR9 is linked to neoplasm.